Is bone mineral density predictive of fracture risk reduction?

Current Medical Research and Opinion

Volumn 20, Issue 3, 2004, Pages 341-349

  Cefalu, Charles A ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Bone density; Fracture; Osteoporosis; Pharmacologic therapy; Treatment outcome

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; ESTROGEN; GESTAGEN; HYDROXYLYSINE; HYDROXYPROLINE; MATRIX METALLOPROTEINASE; OSTEOCALCIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PYRIDINOLINE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN;

ACCURACY; BONE DENSITY; BONE MASS; BONE MINERAL; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; EVALUATION; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; LUMBAR SPINE; MEASUREMENT; MEDLINE; META ANALYSIS; OSTEOPOROSIS; OUTCOMES RESEARCH; POSTMENOPAUSE; PREDICTION; REVIEW; RISK ASSESSMENT; VERTEBRA FRACTURE;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HORMONES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PREDICTIVE VALUE OF TESTS; RISK; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 1542720639     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125003062     Document Type: Review

References (53)

1. Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997;7:390-406
2. National Osteoporosis Foundation. Osteoporosis: Physician's Guide to Prevention and Treatment of Osteoporosis. Belle Meade, NJ: Excerpta Medica; 1999
3. Nelson HD, Helfand M, Woolf SH, et al. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:529-41
4. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129
5. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167:S1-34
6. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368-81
7. Chesnut CH, 3rd, Rose CJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 2001;16:2163-72
8. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9
9. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9
10. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-6
11. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
12. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
13. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45
14. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med 2000;109:267-76
15. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40
16. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
17. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
18. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43
19. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24
20. Eastell R, Watts NB. Osteoporosis: consider the outcomes. Available at: http://www.medscapel.com/viewprogram/1640_pnt. Accessed July 10, 2002
21. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 2001;20:3175-88
22. Watts N, Bockman R, Smith C, et al. BMD change explains only a fraction of the observed fracture risk reduction in risedronate-treated patients [abstract]. Osteoporos Int 2000;11:S203
23. Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002;13:501-5
24. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-3
25. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10
26. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative Randomized Trial. JAMA 2003;290:1729-38
27. Miacalcin (R) (calcitonin salmon, Novartis Pharmaceuticals Corporation, East Hanover, NJ). Full prescribing information, 2003
28. Forteo (R) (teriparatide, Eli Lilly and Company, Indianapolis, IN). Full prescribing information, 2002
29. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
30. Michelotti J, Clark J. Femoral neck length and hip fracture risk. J Bone Miner Res 1999;14:1714-20
31. Oleksik A, Ott SM, Vedi S, et al. Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 2000;15:1368-75
32. Legrand E, Chappard D, Pascaretti C, et al. Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res 2000;15:13-9
33. Borah B, Gross GJ, Dufresne TE, et al. Three-dimensional microimaging (MRmicrol and microCT), finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis. Anat Rec 2001;265:101-10
34. Majumdar S. A review of magnetic resonance (MR) imaging of trabecular bone micro-architecture: contribution to the prediction of biomechanical properties and fracture prevalence. Technol Health Care 1998;6:321-7
35. Hyldstrup L, Jorgensen JT, Sorensen TK, et al. Response of cortical bone to antiresorptive treatment. Calcif Tissue Int 2001;68:135-9
36. Roschger P, Rinnerthaler S, Yates J, et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001;29:185-91
37. Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 2002;17:1139-47
38. Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate (RIS) preserves trabecular architecture in early postmenopausal women in just 1 year: a paired biopsy study using 3D microct [Abstract P69SU]. Osteoporos Int 2002;13:S25
39. Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80
40. Burr DB, Hirano T, Turner CH, et al. Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001;16:157-65
41. Burr DB, Forwood MR, Fyhrie DP, et al. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 1997;12:6-15
42. Ahlborg HG, Johnell O, Nilsson BE, et al. Bone loss in relation to menopause: a prospective study during 16 years. Bone 2001;28:327-31
43. Parfitt AM. Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone 1992;13(Suppl 2):S41-7
44. Parfitt AM. High bone turnover is intrinsically harmful: two paths to a similar conclusion. The Parfitt view. J Bone Miner Res 2002;17:1558-9 [discussion 60]
45. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000;11:S66-76
46. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11:S2-17
47. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000;85:3537-40
48. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999;84:2363-8
49. Yen ML, Yen BL, Jang MH, et al. Effects of alendronate on osteopenic postmenopausal Chinese women. Bone 2000;27:681-5
50. Delmas PD. Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone 2002;30:14-7
51. Watts NB, Adami S, Chesnut C. Risedronate reduces the risk of clinical vertebral fractures in just 6 months [abstract]. J Bone Miner Res 2001;16:S407
52. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6
53. Bjarnason NH, Sarkar S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001;12:922-30